Treatment of leprosy in the changing scenario

References

• World Health Organization. Weekly epidemiological record. No. 32. 81, 309–316 (2006).
   Google Scholar
• Bhattacharya SN, Sehgal VN. Reappraisal of the drifting scenario of leprosy multi-drug therapy: new approach proposed for the new millennium. Int. J. Dermatol.41, 321–326 (2002).
   PubMed Web of Science ®Google Scholar
• Dhople AM. Search for newer antileprosy drugs. Indian J. Lepr.72, 5–20 (2000).
   PubMedGoogle Scholar
• Thakar HG, Kumar A. From vertical to integration for elimination: recent changes in the National Leprosy Eradication Programme in India. Indian J. Public Health47, 191–207 (2003).
   PubMedGoogle Scholar
• WHO Expert Committee on Leprosy. Seventh Report. In: WHO Technical Report Series. World Health Organization, Geneva, Switzerland 874 (1998).
   Google Scholar
• Kundu SK. Features of Ridley-Jopling classification and its application in the clinical field. Int. J. Lepr. Other Mycobact. Dis.47, 64–65 (1979).
   PubMedGoogle Scholar
• Ramesh V, Porichha D. Practical problems in the management of leprosy. Lepr. Rev.67, 330–336 (1996).
   PubMed Web of Science ®Google Scholar
• Jacobson RR. Treatment of leprosy. In: Leprosy (2nd Edition). Hasting RC, Opromolla DVA (Eds). Churchill Livingstone, NY, USA 317–349 (1994).
   Google Scholar
• Chemotherapy of leprosy for control programmes. Report of a WHO study group. In: WHO Technical Report Series. World Health Organization, Geneva, Switzerland 675 (1982).
   Google Scholar
• Chemotherapy of leprosy. Report of a WHO study group. In: WHO Technical Report Series. World Health Organization, Geneva, Switzerland 847 (1994).
   Google Scholar
• Grosset JH. Newer drugs in leprosy. Int. J. Lepr. Other Mycobact. Dis.69(Suppl. 2), S14–S18 (2001).
   PubMedGoogle Scholar
• Grosset JH, Ji B, Guelpa-Lauras CC, Perani EG, N’Deli LN. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis.58, 281–295 (1990).
   PubMedGoogle Scholar
• Ji B, Jamet P, Perani EG, Bobin P, Grosset JH. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J. Infect. Dis.168, 188–190 (1993).
   PubMed Web of Science ®Google Scholar
• Ji B, Grosset JH. Recent advances in the chemotherapy of leprosy. Lepr. Rev.61, 313–329 (1990).
   PubMed Web of Science ®Google Scholar
• Grosset J. The new challenges for chemotherapy research. Lepr. Rev.71(Suppl.), S100–S104 (2000).
   PubMedGoogle Scholar
• Daumerie D. Current World Health Organization-sponsored studies in the chemotherapy of leprosy. Lepr. Rev.71(Suppl.), S88–S90 (2000).
   PubMedGoogle Scholar
• Grosset JH, Cole ST. Genomics and the chemotherapy of leprosy. Lepr. Rev.72, 429–440 (2001).
   PubMed Web of Science ®Google Scholar
• Gelber RH. Leprosy (Hansen’s Disease). In: Harrison’s Principle of Internal Medicine (16th Edition). Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (Eds). Mc Graw-Hill, NY, USA 966–972 (2005).
   Google Scholar
• Lockwood DN, Reid AJ. The diagnosis of leprosy is delayed in the United Kingdom. QJM94, 207–212 (2001).
   PubMed Web of Science ®Google Scholar
• Grandhe NP, Dogra S, Kumar B. Lepromatous leprosy and reversal reaction in a Micronesian immigrant. Int. J. Dermatol.44, 699–700, author reply 700 (2005).
   PubMed Web of Science ®Google Scholar
• Britton WJ, Lockwood DN. Leprosy. Lancet363, 1209–1219 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int. J. Lepr. Other Mycobact. Dis.72, 125–133 (2004).
   PubMedGoogle Scholar
• Naafs B. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Int. J. Lepr. Other Mycobact. Dis.64(Suppl. 4), S21–S28 (1996).
   PubMedGoogle Scholar
• Lockwood DN. Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness. Lepr. Rev.71(Suppl.), S111–S114 (2000).
   PubMedGoogle Scholar
• Naafs B. Treatment duration of reversal reaction: a reappraisal. Back to the past. Lepr. Rev.74, 328–336 (2003).
   PubMed Web of Science ®Google Scholar
• Smith WC, Anderson AM, Withington SG et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). Br. Med. J.328, 1459 (2004).
   PubMed Web of Science ®Google Scholar
• Singal A, Mehta S, Pandhi D. Immune reconstitution inflammatory syndrome in an HIV seropositive leprosy patient. Lepr. Rev.77, 76–80 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan G. Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions. Lepr. Rev.71(Suppl.), S117–S120 (2000).
   PubMed Web of Science ®Google Scholar
• Sehgal VN. Lucio’s phenomenon/erythema necroticans. Int. J. Dermatol.44, 602–605 (2005).
   PubMed Web of Science ®Google Scholar
• Souza CS, Roselino AM, Figueiredo F, Foss NT. Lucio’s phenomenon: clinical and therapeutic aspects. Int. J. Lepr. Other Mycobact. Dis.68, 417–425 (2000).
   PubMedGoogle Scholar
• Srinivasan H. Disability and rehabilitation in leprosy: issues and challenges. Indian J. Lepr.72, 317–337 (2000).
   PubMedGoogle Scholar
• Lockwood DN, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bull. World Health Organ.83, 230–235 (2005).
   PubMed Web of Science ®Google Scholar
• Lockwood DN, Kumar B. Treatment of leprosy. Br. Med. J.328, 1447–1448 (2004).
   PubMed Web of Science ®Google Scholar
• Kasturiaratchi ND, Settinayake S, Grewal P. Processes and challenges: how the Sri Lankan health system managed the integration of leprosy services. Lepr. Rev.73, 177–185 (2002).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Report on eighth meeting of the WHO Technical Advisory Group on Leprosy Control. WHO-SEA-GLP-2006.3.
   Google Scholar
• Ishii N, Nagaoka Y, Mori S, Suzuki K. Leprosy services following elimination in WPRO and SEARO regions. Nihon Hansenbyo Gakkai Zasshi75, 239–248 (2006).
   PubMedGoogle Scholar
• Braber KL. WHO leprosy elimination campaign – beyond 2005. Lepr. Rev.71, 389–391 (2000).
   PubMed Web of Science ®Google Scholar
• Feenstra P, Pannikar V. Partnership for sustainable leprosy control beyond 2005. Lepr. Rev.76, 194–197 (2005).
   PubMed Web of Science ®Google Scholar
• Noordeen SK. Vision beyond 2005. Indian J. Lepr.76, 171–172 (2004).
   PubMedGoogle Scholar
• Kaur I, Dogra S, Kumar B, Radotra BD. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients. Int. J. Lepr. Other Mycobact. Dis.70, 174–181 (2002).
   PubMedGoogle Scholar
• Katoch VM. Advances in the diagnosis and treatment of leprosy. Expert Rev. Mol. Med.2002, 1–14 (2002).
   Google Scholar
• Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet348, 17–24 (1996).
   PubMed Web of Science ®Google Scholar